Department of Pediatric Hematology/Oncology, Istituto Di Ricovero e Cura a Carattere Scientifico, Ospedale Pediatrico Bambino Gesù Rome, Italy ; Università di Pavia Pavia, Italy.
Front Immunol. 2013 Feb 1;4:15. doi: 10.3389/fimmu.2013.00015. eCollection 2013.
Natural killer (NK) cells are involved in innate immune responses and play a major role in tumor surveillance and in defense against viruses. Human NK cells recognize human leukocyte antigen (HLA) class I molecules via surface receptors [killer immunoglobulin-like receptor (KIR) and NKG2A] delivering signals that inhibit NK cell function and kill HLA class I-deficient target cells, a frequent event in tumors or virus-infected cells. NK cell triggering is mediated by activating receptors that recognize ligands expressed primarily on tumors or virus-infected cells. NK cells play also a key role in the cure of high-risk leukemias. Thus, donor-derived "alloreactive" NK cells are fundamental effectors in adult acute myeloid leukemia and in pediatric acute lymphoblastic leukemia patients undergoing haploidentical hematopoietic stem cell transplantation (HSCT). Alloreactive NK cells mediate killing of leukemia cells and patient's dendritic cell, thus preventing respectively leukemic relapses and graft-vs-host responses. Cytofluorimetric analysis of KIRs expressed by NK cells allows to define the size of the alloreactive NK subset and the selection of the best potential donor. Recently, it has been shown that also the expression of activating KIRs, in particular the (C2-specific) KIR2DS1, may contribute to donor NK alloreactivity. It has also been established a correlation between the size of the alloreactive NK cell population and the clinical outcome. Notably, the alloreactive NK cells derived from donor's hematopoietic stem cells are generated and persist in patients over time. The high survival rates of patients undergoing haploidentical HSCT highlight an important new reality in the setting of allograft performed to cure otherwise fatal leukemias. Novel approaches are in progress to further improve the clinical outcome based on the infusion of donor alloreactive NK cells either as a component of the transplanted cell population or as in vitro expanded NK cells.
自然杀伤 (NK) 细胞参与固有免疫反应,在肿瘤监测和防御病毒方面发挥着重要作用。人类 NK 细胞通过表面受体 [杀伤免疫球蛋白样受体 (KIR) 和 NKG2A] 识别人类白细胞抗原 (HLA) Ⅰ类分子,传递抑制 NK 细胞功能和杀伤 HLA Ⅰ类缺失靶细胞的信号,这是肿瘤或病毒感染细胞中的常见事件。NK 细胞的触发是由识别主要表达在肿瘤或病毒感染细胞上的配体的激活受体介导的。NK 细胞在高危白血病的治愈中也起着关键作用。因此,供体来源的“同种异体反应性”NK 细胞是成人急性髓系白血病和接受单倍体造血干细胞移植 (HSCT) 的儿科急性淋巴细胞白血病患者的基本效应物。同种异体反应性 NK 细胞介导对白血病细胞和患者树突状细胞的杀伤,从而分别预防白血病复发和移植物抗宿主反应。通过流式细胞术分析 NK 细胞表达的 KIR 可以定义同种异体反应性 NK 细胞亚群的大小,并选择最佳的潜在供体。最近,已经表明激活的 KIR 的表达,特别是 (C2 特异性) KIR2DS1,也可能有助于供体 NK 的同种异体反应性。还确定了同种异体反应性 NK 细胞群体的大小与临床结果之间存在相关性。值得注意的是,来自供体造血干细胞的同种异体反应性 NK 细胞随着时间的推移在患者体内产生并持续存在。接受单倍体 HSCT 的患者的高生存率突出了在进行同种异体移植以治愈否则致命的白血病的背景下的一个新的重要现实。正在进行新的方法研究,以基于输注供体同种异体反应性 NK 细胞来进一步改善临床结果,无论是作为移植细胞群体的一部分还是作为体外扩增的 NK 细胞。